139 related articles for article (PubMed ID: 10727681)
1. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers.
Kuo WH; Chou FP; Lu SC; Chu SC; Hsieh YS
Clin Chim Acta; 2000 Apr; 294(1-2):157-68. PubMed ID: 10727681
[TBL] [Abstract][Full Text] [Related]
2. Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus.
Chung TW; Kim JR; Suh JI; Lee YC; Chang YC; Chung TH; Kim CH
J Gastroenterol Hepatol; 2004 May; 19(5):565-71. PubMed ID: 15086601
[TBL] [Abstract][Full Text] [Related]
3. Differences in circulating MMP-9 levels with regard to viral load and AST:ALT ratio between chronic hepatitis B and C patients.
Helaly GF
Br J Biomed Sci; 2011; 68(1):38-42. PubMed ID: 21473261
[TBL] [Abstract][Full Text] [Related]
4. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma.
Yeh HC; Lin SM; Chen MF; Pan TL; Wang PW; Yeh CT
Hepatogastroenterology; 2010; 57(97):98-102. PubMed ID: 20422881
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma.
Lin CS; Chang CS; Yang SS; Yeh HZ; Lin CW
Intern Med; 2008; 47(7):569-75. PubMed ID: 18379139
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters.
Fehr T; Riehle HM; Nigg L; Grüter E; Ammann P; Renner EL; Ambühl PM
Am J Kidney Dis; 2003 Jul; 42(1):193-201. PubMed ID: 12830472
[TBL] [Abstract][Full Text] [Related]
9. [The follow-up of serum aminotransferase levels and investigation of hepatitis B virus load in inactive HBsAg carriers].
Olut AI; Ozünlü H; Bozdağ H; Ozkalay N
Mikrobiyol Bul; 2007 Jul; 41(3):429-33. PubMed ID: 17933254
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of alternative serum biomarkers to monitor the progression of chronic HBV and HCV infection.
Tsiomita S; Georgopoulou U; Doumba PP; Koskinas J; Adamidis K; Papaloukas C; Thyphronitis G
Infect Genet Evol; 2018 Mar; 58():17-22. PubMed ID: 29221787
[TBL] [Abstract][Full Text] [Related]
11. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.
Hsu CS; Liu WL; Chao YC; Lin HH; Tseng TC; Wang CC; Chen DS; Kao JH
Hepatol Int; 2015 Apr; 9(2):231-42. PubMed ID: 25788201
[TBL] [Abstract][Full Text] [Related]
12. Genetic diversity, viraemic and aminotransferases levels in chronic infected hepatitis B patients from Cameroon.
Tufon KA; Meriki HD; Anong DN; Mbunkah HA; Nkuo-Akenji T
BMC Res Notes; 2016 Feb; 9():117. PubMed ID: 26899506
[TBL] [Abstract][Full Text] [Related]
13. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection.
Sumida Y; Nakashima T; Yoh T; Nakajima Y; Ishikawa H; Mitsuyoshi H; Sakamoto Y; Okanoue T; Kashima K; Nakamura H; Yodoi J
J Hepatol; 2000 Oct; 33(4):616-22. PubMed ID: 11059866
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
[TBL] [Abstract][Full Text] [Related]
15. Detection of soluble TRAIL in HBV infected patients and its clinical implications.
Han LH; Sun WS; Ma CH; Zhang LN; Liu SX; Zhang Q; Gao LF; Chen YH
World J Gastroenterol; 2002 Dec; 8(6):1077-80. PubMed ID: 12439929
[TBL] [Abstract][Full Text] [Related]
16. [Features of combined (HBV/HCV-infection) viral lesion of the liver].
Maev IV; Nikushkina IN; Samsonov AA; Aksel'rod AG
Ter Arkh; 2008; 80(2):57-61. PubMed ID: 18372598
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen in late hepatitis B infection.
Zeng DW; Zhu YY; Huang Q; Zhang JM; Wu YL; Dong J; Jiang JJ; Liu YR
J Med Virol; 2015 Mar; 87(3):380-7. PubMed ID: 25604455
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to non-structural hepatitis C virus antigens: a link with liver disease activity?
Gessoni G; Manoni F
Eur J Med; 1992 Sep; 1(5):288-94. PubMed ID: 1285245
[TBL] [Abstract][Full Text] [Related]
19. Serological survey of viral hepatitis markers among newly diagnosed patients with HIV/AIDS in China.
Shen YZ; Wang ZY; Qi TK; Jiang XY; Song W; Tang Y; Wang JR; Liu L; Zhang RF; Zheng YF; Dai ZS; Lu HZ
HIV Med; 2013 Mar; 14(3):167-75. PubMed ID: 22998624
[TBL] [Abstract][Full Text] [Related]
20. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.
Huo TI; Wu JC; Lee PC; Chau GY; Lui WY; Tsay SH; Ting LT; Chang FY; Lee SD
Hepatology; 1998 Jul; 28(1):231-6. PubMed ID: 9657117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
